Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I, Liens D, Godfrin Y, Rigal D, Bertrand Y. Domenech C, et al. Among authors: mechinaud f. Br J Haematol. 2011 Apr;153(1):58-65. doi: 10.1111/j.1365-2141.2011.08588.x. Epub 2011 Feb 20. Br J Haematol. 2011. PMID: 21332712 Free article. Clinical Trial.
Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
Bellott R, Auvrignon A, Leblanc T, Pérel Y, Gandemer V, Bertrand Y, Méchinaud F, Bellenger P, Vernois J, Leverger G, Baruchel A, Robert J. Bellott R, et al. Among authors: mechinaud f. Cancer Chemother Pharmacol. 2001;47(1):15-21. doi: 10.1007/s002800000206. Cancer Chemother Pharmacol. 2001. PMID: 11221955 Clinical Trial.
Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthou C, Galambrun C, Bernard F, Yacouben K, Bordigoni P, Edan C, Reguerre Y, Couillault G, Méchinaud F, Cayuela JM, Guilhot F. Millot F, et al. Among authors: mechinaud f. J Clin Oncol. 2011 Jul 10;29(20):2827-32. doi: 10.1200/JCO.2010.32.7114. Epub 2011 Jun 13. J Clin Oncol. 2011. PMID: 21670449 Clinical Trial.
Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V, Pochon C, Oger E, Dalle JH, Michel G, Schmitt C, de Berranger E, Galambrun C, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rorhlich P, Lutz P, Demeocq F, Schneider P, Plantaz D, Poirée M, Bordigoni P. Gandemer V, et al. Among authors: mechinaud f. Br J Haematol. 2014 May;165(3):392-401. doi: 10.1111/bjh.12749. Epub 2014 Jan 30. Br J Haematol. 2014. PMID: 24479958 Free article. Clinical Trial.
Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.
Pochon C, Oger E, Michel G, Dalle JH, Salmon A, Nelken B, Bertrand Y, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rohrlich P, Paillard C, Demeocq F, Schneider P, Plantaz D, Poirée M, Eliaou JF, Semana G, Drunat S, Jonveaux P, Bordigoni P, Gandemer V. Pochon C, et al. Among authors: mechinaud f. Br J Haematol. 2015 Apr;169(2):249-61. doi: 10.1111/bjh.13272. Epub 2014 Dec 19. Br J Haematol. 2015. PMID: 25522886 Free article.
Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials.
Simon P, Suciu S, Clappier E, Cave H, Sirvent N, Plat G, Thyss A, Mechinaud F, Costa VM, Ferster A, Lutz P, Mazingue F, Plantaz D, Plouvier E, Bertrand Y, Benoit Y, Dastugue N, Rohrlich PS; Children’s Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC). Simon P, et al. Among authors: mechinaud f. Ann Hematol. 2016 Jan;95(1):93-103. doi: 10.1007/s00277-015-2515-8. Epub 2015 Oct 12. Ann Hematol. 2016. PMID: 26455579 Clinical Trial.
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Shah NN, Bhojwani D, August K, Baruchel A, Bertrand Y, Boklan J, Dalla-Pozza L, Dennis R, Hijiya N, Locatelli F, Martin PL, Mechinaud F, Moppett J, Rheingold SR, Schmitt C, Trippett TM, Liang M, Balic K, Li X, Vainshtein I, Yao NS, Pastan I, Wayne AS. Shah NN, et al. Among authors: mechinaud f. Pediatr Blood Cancer. 2020 May;67(5):e28112. doi: 10.1002/pbc.28112. Epub 2020 Jan 15. Pediatr Blood Cancer. 2020. PMID: 31944549 Free PMC article. Clinical Trial.
Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cavé H, Baila L, Bertrand Y; Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC). Uyttebroeck A, et al. Among authors: mechinaud f. Eur J Cancer. 2008 Apr;44(6):840-6. doi: 10.1016/j.ejca.2008.02.011. Epub 2008 Mar 14. Eur J Cancer. 2008. PMID: 18342502 Clinical Trial.
SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Bertrand Y, Mechinaud F, Brethon B, Mialou V, Auvrignon A, Nelken B, Notz-Carrère A, Plantaz D, Patte C, Urbieta M, Baruchel A, Leverger G; SFCE. Bertrand Y, et al. Among authors: mechinaud f. J Pediatr Hematol Oncol. 2008 Apr;30(4):267-71. doi: 10.1097/MPH.0b013e318162bd41. J Pediatr Hematol Oncol. 2008. PMID: 18391694
176 results